DKCM
KPTI icon

Davidson Kempner Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Davidson Kempner Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67M Sell
300,000
-10,020
-3% -$76.4K 0.02% 171
2025
Q4 		$2.28M Buy
+310,020
New +$1.9M 0.03% 156

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Davidson Kempner Capital Management's KPTI Position: Q1 2026 in Review

Davidson Kempner Capital Management reduced its Karyopharm Therapeutics (KPTI) stake by 3.2% in Q1 2026, selling an estimated $76.4K and leaving 300,000 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #171.

Davidson Kempner Capital Management first reported a position in KPTI in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.28M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Davidson Kempner Capital Management held 300,000 shares of Karyopharm Therapeutics worth $1.67M as of Q1 2026.
  • Davidson Kempner Capital Management sold 10,020 Karyopharm Therapeutics shares in Q1 2026, an estimated $76.4K.
  • Karyopharm Therapeutics made up 0.02% of Davidson Kempner Capital Management's portfolio in Q1 2026, its #171 holding.
  • Davidson Kempner Capital Management first reported a position in Karyopharm Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Davidson Kempner Capital Management's Karyopharm Therapeutics position peaked at $2.28M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2026, filed 15 May 2026.